In the past decade, the introduction of newer potent P2Y12 inhibitors (e.g., ticagrelor and prasugrel) has helped to further reduce the occurrence of ischemic events in coronary artery disease (CAD) patients [5]. Here, P2RY12 is linked to coronary artery disorder.